Model of metastatic growth valuable for radionuclide therapy

Medical Physics

Volumn 30, Issue 12, 2003, Pages 3227-3232

  Bernhardt, Peter ^a   Ahlman, Håkan ^a   Forssell Aronsson, Eva ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Metastatic growth; Monte Carlo; Radionuclide therapy

Indexed keywords

CURING; DIAGNOSIS; MONTE CARLO METHODS; PATHOLOGY; RADIOISOTOPES; SIZE DISTRIBUTION; TUMORS;

ACTIVITY CONCENTRATION; ACTIVITY DISTRIBUTION; HEPATOCELLULAR CARCINOMA; HIGH-ENERGY ELECTRON; LOW ENERGY ELECTRONS; MEDIUM-ENERGY ELECTRON; METASTATIC GROWTH; RADIONUCLIDE THERAPY;

ELECTRONS;

LUTETIUM; LUTETIUM 177; RADIOISOTOPE; RHODIUM; RHODIUM 103M; UNCLASSIFIED DRUG; YTTRIUM 90;

ARTICLE; CASE REPORT; HUMAN; LIVER CELL CARCINOMA; MATHEMATICAL MODEL; METASTASIS; MONTE CARLO METHOD; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; SIMULATION; TUMOR GROWTH;

EID: 0346364985     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.1628851     Document Type: Article

References (21)

1. P. Bernhardt, E. Forssell-Aronsson, L. Jacobsson, and G. Skarnemark, "Low-energy electron emitters for targeted therapy of small tumors," Acta Oncol. 41, 602-608 (2001).
2. J. A. O'Donoghue, M. Bardies, and T. E. Wheldon, "Relationship between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides," J. Nucl. Med. 36, 1902-1909 (1995).
3. K. Iwata, K. Kawasaki, and N. Shigesada, "A dynamical model for the growth and size distribution of multiple metastatic tumors," J. Theor. Biol. 203, 177-186 (2000).
4. M. Gyllenberg and G. F. Webb, "Non-linear structured population model of tumor growth with quiescence," J. Math. Biol. 28, 671-694 (1990).
5. E. Browne and R. B. Firestone, Table of Radioactive Isotopes (Wiley-Interscience, New York, NY. 1986).
6. R. W. Howell, D. V. Rao, and C. Haydock, "Dosimetry techniques for therapeutic applications of incorporated radionuclides," in The Joint Symposium on Dosimetry of Administered Radionuclides, Proceedings held at Washington DC, 1989, September, pp. 215-256.
7. M. J. Berger, "Improved point kernels for electron and beta ray dosimetry," National Bureau of Standards, NBSIR 73-107, Washington, 1973.
8. D. Hart, E. Shochat, and Z. Agur, "The growth law of primary breast cancer as inferred from mammography screening trials data," Br. J. Cancer 78, 382-387 (1998).
9. A. Akanuma, "Parameter analysis of Gompertzian function growth model in clinical tumors," Eur. J. Cancer 14, 681-688 (1978).
10. L. A. Loitta, G. M. Saidel, and J. Kleinerman, "The significance of hematogenous tumor cell clumps in the metastatic process," Cancer Res. 36, 889-894 (1976).
11. K. Pistevou-Gombaki, N. Eleftheriadis, G.A. Plataniotis, I. Sofroniadis, and V. E. Kouloulias, "Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLO-C30 questionaire," Palliative Med. 17, 257-262 (2003).
12. 111In-DTPAo] octreotide in patients," Eur. J. Nucl. Med. 28, 1319-1325 (2001).
13. G. Paganelli et al., "Receptor-mediated radiotherapy with 90Y-DOTA-D-Phel-Tyr3-octreotide," Eur. J. Nucl. Med. 28, 426-434 (2001).
14. P. Bernhardt, S. A. Benjegård, L. Kolby, V. Johanson, O. Nilsson, H. Ahlman, and E. Forssell-Aronsson, "Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors," Int. J. Radiat. Oncol., Biol., Phys. 51, 514-524 (2001).
15. J. F. Fowler, "Radiobiological aspects of low dose rates in radiommunotherapy," Int. J. Radiat. Oncol., Biol., Phys. 18, 1261-1269 (1990).
16. R. G. Dale, "Dose-rate effects in targeted radiotherapy," Phys. Med. Biol. 41, 1871-1884 (1996).
17. C. R. Mitchell, M. Folkard, and M. C. Joiner, "Effects of exposure to low-dose-rate Co gamma rays on human tumor cells in vitro.," Radiat. Res. 158, 311-318 (2002).
18. E. Forssell-Aronsson, M. Fjälling, O. Nilsson, B. Wängberg, and H. Ahlman, "In activity concentration in human samples after i.v. injection of In-DTPA-Phe-octreotide," J. Nucl. Med. 36, 7-12 (1995).
19. 1-octreotide," J. Nucl. Med. 37, 2002-2006 (1996).
20. 111In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors," Cancer Biother Radiopharm. 18, 249-252 (2003).
21. 0]octreotide" J. Nucl. Med. 44, 98-104 (2003).